Title: Efficacy of Olaparib in BRCA-Mutated Breast Cancer
Abstract: Olaparib, a PARP inhibitor, showed significant efficacy in
BRCA1/2-mutated metastatic breast cancer patients (N=302, RCT).
Response rate: 59.9% (95% CI: 52-66%, p<0.001).